Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-01-04 @ 4:29 PM
Study NCT ID:
NCT02644967
Status:
COMPLETED
Last Update Posted:
2022-08-03
First Post:
2015-12-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
Sponsor:
Idera Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-12
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05
Completion Date Type:
ACTUAL
First Submit Date:
2015-12-23
First Submit QC Date:
None
Study First Post Date:
2016-01-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-02-10
Results First Submit QC Date:
None
Results First Post Date:
2022-08-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-08
Last Update Post Date:
2022-08-03
Last Update Post Date Type:
ACTUAL